European Medicines Agency (EMA) has begun a rolling review for updated versions of Moderna’s and Pfizer/BioNTech’s vaccines modified to optimize protection against newer variants of SARS-CoV-2. Earlier this month, Moderna (Nasdaq:MRNA) announced that its Omicron-containing bivalent COVID-19 booster candidate, mRNA-1273.21, provided an antibody response that was statistically superior to the original version of the vaccine,…
Moderna’s omicron bivalent COVID-19 vaccine outperformed original vaccine in analysis
Moderna (Nasdaq:MRNA) has announced that its omicron-containing bivalent COVID-19 booster candidate mRNA-1273.214 yielded 1.75 times more neutralizing antibodies than its FDA-approved mRNA-1273 vaccine. The company also noted that a booster dose of mRNA-1273.214 increased neutralizing geometric mean titers (GMT) against the omicron variant roughly eight times over baseline levels in the primary immunogenicity study. The…
Moderna commences Phase 2 study of omicron-specific booster
Mere days after rivals Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX) announced the launch of a study testing an omicron-based booster vaccine candidate, Moderna (NSDQ:MRNA) has announced its own trial of an omicron-specific vaccine. The vaccine booster candidate, mRNA-1273.529, will be the subject of a Phase 2 study involving approximately 600 participants divided into two cohorts. The…
Europe orders another 150 million doses of Moderna’s COVID-19 vaccine
Moderna (NSDQ:MRNA) has announced that the European Commission has reserved an additional 150 million doses of its COVID-19 vaccine for delivery in 2022. To date, the European Commission has reserved 460 million Moderna vaccine doses. The new deal gives the European Commission the ability to purchase new COVID-19 vaccines. The company is currently testing various…
Moderna vaccine highly effective two weeks after first dose
A study published in JAMA involving healthcare workers found that the first dose of Moderna’s (NSDQ:MRNA) COVID-19 vaccine was highly effective at reducing the risk of COVID-19 infections. In the study, participants received two doses of the vaccine at the recommended 28-day interval. Clinical effectiveness reached 95% for days 15 through 42 of the study.…
Moderna’s COVID-19 vaccine 100% effective in teens
Moderna (NSDQ:MRNA) has joined Pfizer (NYSE:PFE) in announcing that its vaccine was 100% effective in a Phase 2/3 study involving adolescents. It will seek regulatory authorization to expand the use of its vaccine to adolescents as young as 12 in early June. In the TeenCOVE study, no participants who received two doses of the mRNA-1273…
Moderna and Pfizer COVID-19 vaccines set a high bar for competitors
Moderna (NSDQ:MRNA) is now the second company to release positive preliminary results from a Phase 3 trial of a COVID-19 vaccine candidate — and it appears to be more good news. Last week, Pfizer (NYSE:PFE) announced that early data suggested its BNT162 mRNA-based vaccine was more than 90% effective at reducing symptomatic COVID-19 infections. Today,…
Moderna readies interim analysis for its COVID-19 vaccine trial
Pfizer (NYSE:PFE) and Moderna (NYSE:MRNA) are likely to be among the first companies to commercialize COVID-19 vaccines. But while the former has announced positive results from its interim analysis of its clinical study, the status of Moderna’s Phase 3 COVE trial remains a mystery. The company announced that it remains blinded to whether the Phase 3…